Formulation Development
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV & hMPV in Older Adults
Icosavax, Inc. recently announced the initiation of a Phase 2 clinical trial of IVX-A12, a combination bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV)…
Curia Expands Cell Line Development Offering With CHOZN Platform
Curia signs license agreement with MilliporeSigma to support production of proteins and antibodies….
Thaerapy BV & Resyca BV Announce Exclusive License Agreement for Soft Mist Inhaler Technology
Thaerapy BV and Resyca BV a joint venture of Medspray Pharma BV and Recipharm AB, a leader in the development of soft mist inhalers, recently announced today the signing of an exclusive license agreement for Resyca’s soft mist….
Celanese & Nanoform Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants
Celanese and Nanoform Finland Plc recently provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery…..
ANAVEX2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients With Rett Syndrome
Anavex Life Sciences Corp. recently announced the first patients with Rett syndrome from the ANAVEX2-73-RS-003 study (EXCELLENCE) are able to continue treatment with ANAVEX2-73 (blarcamesine)…
Helocyte Announces $3.22-Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (CMV) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk of CMV events in high-risk transplant recipients….
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b Trial of Rencofilstat
Hepion Pharmaceuticals, Inc. recently announced the Data and Safety Monitoring Board (DSMB) has met to review the current data for the ASCEND-NASH Phase 2b trial…
Ventyx Biosciences Announces Initiation of Dosing in Phase 1 Trial of Novel CNS-Penetrant NLRP3 Inhibitor
Ventyx Biosciences, Inc. recently announced the first subject has been dosed in a Phase 1 trial of VTX3232, a novel central nervous system (CNS)-penetrant NLRP3…
HCW Biologics Granted Third Fundamental Patent for Methods of Treating Age-Related Disorders
HCW Biologics Inc. was granted US Patent No. 11,672,826 on June 13, 2023, which contains methods of use claims directed to administering the company’s clinical-stage…
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech, Inc. recently announced the signing of an Asset Purchase Agreement with WraSer, LLC and Xspire Pharma, LLC for the purchase of six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain….
PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 & KEYTRUDA in Head & Neck Cancer
PDS Biotechnology Corporation recently announced it achieved the threshold for efficacy as per investigator assessment in Stage 2 of the VERSATILE-002 (NCT04260126) Phase 2 clinical…
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder
PaxMedica, Inc. recently announced it has submitted a request to the South African Health Products Regulatory Authority (SAHPRA), seeking approval to conduct a double-blind, placebo-controlled…
Valo Therapeutics & Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase 1 Clinical Study
Valo Therapeutics Oy recently announced a collaboration with global contract research organization, Texcell, to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study.…
Salipro Biotech Expands Global Intellectual Property Portfolio With Granted Patent in Japan
Salipro Biotech AB recently announce the issuance of a new patent in Japan for its Salipro platform technology. The patent, titled Saposin lipoprotein particles and…
Mustang Bio Announces Updated Results From Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
Mustang Bio, Inc. recently announced that updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, show…
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
Phathom Pharmaceuticals, Inc. recently announced the US FDA has acknowledged that its New Drug Application (NDA) resubmission for vonoprazan, a novel first-in-class potassium-competitive acid blocker…
ABVC BioPharma ADHD Phase 2 Part 2 Clinical Study First Subject Enrolled at UCSF
ABVC BioPharma, Inc. recently announced the first subject was enrolled at University of California San Francisco (UCSF) Medical Center on June 9, 2023. The UCSF…
WHITEPAPER - Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion & Polyvinyl Alcohol
This white paper describes how hot melt extrusion (HME) and a specially-engineered grade of polyvinyl alcohol can be used to increase the solubility of DCS IIb molecules.
Quell Therapeutics Signs Collaboration, Exclusive Option & License Agreement With AstraZeneca to Develop, Manufacture & Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases
Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial capabilities as well as its deep therapeutic area knowledge….
Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety & Pharmacodynamic Data for a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy
Daré Bioscience, Inc. recently announced the publication of results of its Phase 1/2 clinical study of DARE-VVA1, a proprietary, investigational formulation of tamoxifen for intravaginal…
